Table 1.

Summary of pharmacokinetic characteristics of rivaroxaban at steady state based on phase II data

Parameter	Rivaroxaban dose
	2.5 mg bid*	2.5 mg bid#	5 mg bid*	10 mg bid*	20 mg bid*	30 mg bid‡
AUC (μg.h/l)	300	328	464	974	1764	6500
Cmax (μg/l)	53	40	86	180	299	400
Ctrough (μg/l)	8	14	11	38	68	160

*Data are mean values from an analysis of the ODIXa-HIP2 study [17]. ^#Data are median values from an analysis of the ATLAS ACS TIMI 46 study (subset of patients aged <50 years) [18]. ^‡Data are mean values from an analysis of the ODIXa-DVT study [19].

Abbreviations: AUC area under the concentration–time curve, bid twice daily, C_max maximum plasma concentration, C_trough minimum plasma concentration.